Cargando…

The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant

The number of pregnant women with cancer is on the rise. These patients and their providers encounter complex medical management decisions. Standard-of-care systemic therapy and radiological imaging can impair fetal development and affect viability. Conversely, insufficient monitoring and treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohen, Stacey A., Kasi, Anup, Hook, Nicole, Krainock, Michael, Budde, Griffin, Malashevich, Allyson Koyen, Meltzer, Jeffrey, Jelsema, Russ, Olshan, Perry, Billings, Paul R., Aleshin, Alexey, Poklepovic, Andrew S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941578/ https://www.ncbi.nlm.nih.gov/pubmed/35342654 http://dx.doi.org/10.1155/2022/9412201

Ejemplares similares

Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2022)

ctDNA Clearance and Radiographic Resolution of Disease in Response to Dual Checkpoint Inhibition in Metastatic Microsatellite Stable Colorectal Cancer with a High Tumor Mutation Burden
por: Schneider, Charles J., et al.
Publicado: (2021)

Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma
por: Azzi, Georges, et al.
Publicado: (2022)

Clinician‐reported chorionicity and zygosity assignment using single‐nucleotide polymorphism‐based cell‐free DNA: Lessons learned from 55,344 twin pregnancies
por: Wojas, Anna, et al.
Publicado: (2022)

BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2022)

Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios
por: Khaddour, Karam, et al.
Publicado: (2022)

Feasibility of Longitudinal ctDNA Assessment in Patients with Uterine and Extra-Uterine Leiomyosarcoma
por: Zhou, Maggie, et al.
Publicado: (2022)

BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2021)

Treatment Response Monitoring Using a Tumor-Informed Circulating Tumor DNA Test in an Advanced Triple-Negative Breast Cancer Patient: A Case Report
por: Azzi, Georges, et al.
Publicado: (2022)

Early Detection of Circulating Tumor DNA Postoperatively Enables Discovery of Resectable Metastatic Disease in a Patient with Colon Cancer
por: Weinberg, Benjamin A., et al.
Publicado: (2021)

Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
por: Chakrabarti, Sakti, et al.
Publicado: (2022)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

Association Between Total Cell Free DNA and SARS-CoV-2 In Kidney Transplant Patients: A Preliminary Study
por: Reusing, Jose Otto, et al.
Publicado: (2022)

Pregnant women become insensitive to cold stress
por: Kammerer, Martin, et al.
Publicado: (2002)

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases
por: Loupakis, Fotios, et al.
Publicado: (2021)

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
por: Khatami, Fatemeh, et al.
Publicado: (2018)

Liquid Biopsy, ctDNA Diagnosis through NGS
por: Lin, Chen, et al.
Publicado: (2021)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022)

State of the Art: ctDNA in Upper Gastrointestinal Malignancies
por: Labiano, Ibone, et al.
Publicado: (2023)

Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer
por: Todenhöfer, Tilman, et al.
Publicado: (2018)

ctDNA Detection Based on DNA Clutch Probes and Strand Exchange Mechanism
por: Chang, Huan, et al.
Publicado: (2018)

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
por: Chiu, Joanne, et al.
Publicado: (2023)

Fear of becoming pregnant among female healthcare students in Spain
por: Navarro-Cremades, Felipe, et al.
Publicado: (2015)

Concurrent Opioid and Alcohol Use Among Women Who Become Pregnant: Historical, Current, and Future Perspectives
por: Klaman, Stacey L, et al.
Publicado: (2019)

Detection of ctDNA in the plasma of patients with papillary thyroid carcinoma
por: Li, Huiqiang, et al.
Publicado: (2019)

ctDNA: An emerging neoadjuvant biomarker in resectable solid tumors
por: Abbosh, Christopher, et al.
Publicado: (2021)

Current status of ctDNA in precision oncology for hepatocellular carcinoma
por: Li, Yan, et al.
Publicado: (2021)

The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma
por: Ding, Yubo, et al.
Publicado: (2022)

Current and Future Clinical Applications of ctDNA in Immuno-Oncology
por: Stadler, Julia-Christina, et al.
Publicado: (2022)

Regulatory implications of ctDNA in immuno-oncology for solid tumors
por: Vellanki, Paz J, et al.
Publicado: (2023)

CTC, ctDNA, and Exosome in Thyroid Cancers: A Review
por: Wang, Wenwen, et al.
Publicado: (2023)

A dual biomarker detection platform for quantitating circulating tumor DNA (ctDNA)
por: Cai, Chunyan, et al.
Publicado: (2018)

Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer
por: Zhou, Yidong, et al.
Publicado: (2019)

Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
por: Dao, Jonathan, et al.
Publicado: (2023)

ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy
por: Lebow, Emily S., et al.
Publicado: (2023)

Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA)
por: Gilson, Pauline, et al.
Publicado: (2021)

Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer
por: Duffy, Michael J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4ug0m4taq93fs9cr9kcrag21hq